KIRYAT ONO, Israel & NEW YORK--(BUSINESS WIRE)--GammaCan International, Inc. (OTC BB: GCAN), a developer of immunotherapies for the treatment of cancer, today announced that Patrick Schnegelsberg, Chief Executive Officer, is scheduled to present VitiGam, GammaCan’s lead product under development for the treatment of stage III and IV melanoma, to the investor, biotechnology and pharma communities at the BioPartnering North America Conference.
